MTFB - Motif Bio plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.3255
-0.6245 (-5.7032%)
At close: 1:04PM EDT
Stock chart is not supported by your current browser
Previous Close10.9500
Open10.3255
Bid9.3000 x 500
Ask10.6500 x 100
Day's Range10.3255 - 10.3255
52 Week Range6.8370 - 13.7500
Volume100
Avg. Volume2,330
Market Cap129.324M
Beta0.46
PE Ratio (TTM)N/A
EPS (TTM)-3.8800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • GlobeNewswire3 days ago

    Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018

    NEW YORK, April 19, 2018--. Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data continue ...

  • GlobeNewswire5 days ago

    Posting of UK Annual Report and Accounts & Notice of AGM

    NEW YORK, April 17, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual Report and Accounts and notice ...

  • GlobeNewswire11 days ago

    Motif Bio Announces Iclaprim Abstracts for ECCMID 2018 Now Online

    NEW YORK, April 11, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that iclaprim-related abstracts are now online for the upcoming ...

  • GlobeNewswire12 days ago

    Motif Bio Reports Fiscal Year 2017 Results

    NEW YORK, April 10, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2017.. ...

  • GlobeNewswire19 days ago

    Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update

    NEW YORK, April 03, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling submission of a New Drug Application ...

  • Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?
    Simply Wall St.last month

    Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?

    Motif Bio plc (NASDAQ:MTFB), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. WithRead More...

  • GlobeNewswirelast month

    Motif Bio Update on NDA Submission for Iclaprim

    NEW YORK, March 20, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of ...

  • GlobeNewswirelast month

    Motif Bio to present at upcoming investor and scientific conferences

    NEW YORK, March 19, 2018-- Motif Bio plc, a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at the following conferences in ...

  • GlobeNewswire2 months ago

    Motif Bio to Present Iclaprim Data at ECCMID 2018

    Phase 3 trial results for REVIVE-2 in patients with ABSSSI Potential cost savings opportunities with iclaprim versus vancomycin Iclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018-- Motif Bio ...

  • GlobeNewswire3 months ago

    Appointment of Jonathan E. Gold as Interim Chief Financial Officer

    NEW YORK, Feb. 02, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Dickey IV has informed the Company of his intention ...

  • Zacks Small Cap Research3 months ago

    MTFB: REVIVE-1 Results Published in Clinical Infectious Diseases

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. The company had previously announced positive topline results from the study in April 2017.

  • PR Newswire3 months ago

    Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

    WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.

  • Should You Buy Motif Bio plc (AIM:MTFB) Now?
    Simply Wall St.6 months ago

    Should You Buy Motif Bio plc (AIM:MTFB) Now?

    Motif Bio plc (AIM:MTFB), a pharmaceuticals company based in United States, saw a significant share price rise of over 20% in the past couple of months on the AIM. WithRead More...

  • Zacks Small Cap Research7 months ago

    MTFB: Positive Results From Second Phase 3 Study of Iclaprim; NDA Filing Anticipated in 1Q18

    On October 4, 2017, Motif Bio (MTFB) announced positive topline results from REVIVE-2, the second Phase 3 clinical trial of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI). With positive results from two Phase 3 clinical trials, we anticipate Motif filing a New Drug Application (NDA) in the first quarter of 2018 and with a six-month review (based on Fast Track status), iclaprim could be approved for the treatment of ABSSSI before the end of 2018. The REVIVE Phase 3 program for iclaprim in the treatment of ABSSSI included two randomized, double blind clinical trials (REVIVE-1 and REVIVE-2).

  • Why You Need To Look At This Factor Before Buying Motif Bio plc (MTFB)
    Simply Wall St.7 months ago

    Why You Need To Look At This Factor Before Buying Motif Bio plc (MTFB)

    If you are a shareholder in Motif Bio plc’s (NASDAQ:MTFB), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...